In what co-founder and CEO Claudia Ulbrich called the “right decision with right partner at the right point in time,” Cardior Pharmaceuticals GmbH agreed to an acquisition by Novo Nordisk A/S in a deal worth up to €1.025 billion (US$1.1 billion) that puts a potentially disease-modifying heart failure candidate in the hands of a big pharma player in the midst of establishing its presence in cardiovascular disease.
While preparing a follow-on phase III study of its Cardiamp cell therapy, Biocardia Inc. has mined positive interim data at a mean 20-month follow-up of all patients in the original Cardiamp HF Trial.
Heart failure with preserved ejection fraction (HFpEF) has limited treatment options and remains a medical challenge. HFpEF is characterized by diastolic dysfunction with a normal ejection fraction. Previous findings have shown that inhibiting histone deacetylase 6 (HDAC6) alters the mechanisms contributing to dilated cardiomyopathy.
Researchers from the Academic Medical Center (AMC) University of Amsterdam are seeking protection for their invention of a total artificial heart which is compact, durable and mimics the natural movement of human tissue.
Windtree Therapeutics Inc. has renewed its partnership with Chang Gung University to further research on SERCA2a, an important target for the company’s cardiovascular portfolio.
The $4.5 million in seed funding that Acorai AB recently raised will allow the company to continue its forward momentum in developing its technology to support the treatment of patients living with heart failure, Matthew Mace, co-founder and chief scientific officer told BioWorld. In practice, this means that with the funds the company will be able to meet its “projected timelines on the path toward regulatory approval in the U.S., focus on market entry and get the device into the hands of health care professionals sooner.”
The U.S. FDA has granted Mesoblast Ltd.’s allogeneic cell therapy Revascor (rexlemestrocel-L) rare pediatric disease designation following submission of results from a clinical trial in children with hypoplastic left heart syndrome, a potentially life-threatening congenital heart condition.
The U.S. FDA has granted Mesoblast Ltd.’s allogeneic cell therapy Revascor (rexlemestrocel-L) rare pediatric disease designation following submission of results from a clinical trial in children with hypoplastic left heart syndrome, a potentially life-threatening congenital heart condition.
There is a strong relationship between heart failure (HF) and atrial fibrillation (AF): half of the patients with HF acquire AF. Recent studies discovered a genetic basis underlying AF, which demonstrated a strong heritable component to this disease.